eLearning module: Immunogenicity
In this expert authored eLearning module, Professor Huub Schellekens explains the concept of immunogenicity and how it affects the safety of biosimilars. This module also provides some considerations on how to interpret immunogenicity data in clinical practice.
This module will take up to 20 minutes to complete.
On completion of the eLearning module, you will be able to:
- Explain the factors that contribute to, and the consequences of, immunogenicity of biosimilars.
- Discuss the design and importance of immunogenicity assessments during the development of biosimilars.
All medical oncologists, specialist nurses, and allied healthcare professionals working with patients for whom biosimilars may represent a treatment option.